CAH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cardinal Health (CAH) does not present a strong buy opportunity at this time for a beginner investor with a long-term strategy. The stock is experiencing a downward price trend, lacks significant positive catalysts, and has mixed analyst sentiment. While the company has strong fundamentals and a durable competitive moat, the absence of recent trading signals and the lack of significant growth momentum suggest holding off on an investment for now.
The technical indicators show a mixed picture. While the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD is positively contracting, and RSI is neutral at 63.15. The stock is trading near its pivot level of 216.471, with resistance at 227.465 and support at 205.477. However, the regular market change of -1.99% suggests a short-term bearish trend.
Analysts highlight Cardinal Health's durable competitive moat and strong pharmaceutical distribution platform, which positions the company well for long-term growth. Additionally, the company raised FY26 EPS guidance, reflecting strength in its Pharma/Other segments.
Recent price target reductions by multiple analysts and the lack of significant insider or hedge fund trading activity indicate limited near-term upside. The stock's recent price decline and bearish sentiment in options trading further weigh against a buy recommendation.
No financial data is available for the latest quarter, but analysts noted a mixed-to-positive Q3 with raised FY26 EPS guidance. However, this was driven by below-the-line items rather than core operational growth.
Analyst sentiment is mixed, with several firms lowering price targets while maintaining Buy or Outperform ratings. JPMorgan downgraded its price target to $215, while TD Cowen raised it to $255. The consensus reflects cautious optimism but no strong bullish momentum.
